What is your preferred frontline treatment for CLL in young patients < 50 years old?

For younger patients, just like older patients with CLL, my preference for frontline treatment is based on genomic characteristics, fitness, and patient preference. I also prefer clinical trials over standard therapy, when available.

For those young fit patients with IGHV mutated disease, the option...

My preferred treatment (for any patient with CLL) is based on a combination of medical comorbidities (especially cardiovascular, pulmonary, and immune), patients' preferences, and willingness to accept certain potential toxicities and disease characteristics (esp TP53 aberrations, IgHV mutation stat...

Targeted therapy with a BTK inhibitor or a fixed-duration regimen of venetoclax plus obinutuzumab has replaced chemoimmunotherapy due to superior progression-free and overall survival. The choice between these regimens is individualized based on patient comorbidities, genetic risk factors (e.g., TP5...

As above endorsement by @Dr. First Last, I am in very general agreement with @Dr. First Last's approach to the young CLL patient. Want to endorse the comment that for the low risk (FISH normal and no p53 mutations with IGHV mutated status) young, fit CLL patient that chemoimmunotherapy (CIT) is stil...

For those without del17p and with IGHV UM, acala/ven/obin. If they have mutated IGHV, then would consider just ven obin, but it would be a conversation. For those with del17p, I would either do continuous BTKI, but I am now often shifting to the acala/ven/obin MRD guided that our group published in ...